GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nitroxoline   Click here for help

GtoPdb Ligand ID: 13964

Synonyms: APL-1202 | APL1202 | compound 10 [PMID: 30939017]
Approved drug PDB Ligand
nitroxoline is an approved drug
Compound class: Synthetic organic
Comment: Nitroxoline is an antimicrobial used to treat urinary tract infections [3]. Repurposing of nitroxoline for infectious diseases and oncological indications has been proposed, although pharmacokinetic challenges are likely to hamper clinical translation.

From a patent it would appear that Healx Ltd. are interested in pursuing nitroxoline for the treatment of plexiform neurofibroma/neurofibromatosis type 1 (NF1) [1]. Review of Healx's active pipeline (January 2026) reveals two candidates with codes HLX-1502 and HLX-0213 in development for NF1 [4]. HLX-1502 has reached phase 2 whereas HLX-0213 is in the discovery phase (at time of writing), so it is plausible that HLX-1502 is nitroxoline. We await formal disclosure of this potential association.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 75.73
Molecular weight 190.16
XLogP 0.8
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=CN=C2C(=C1)C(=CC=C2O)[N+](=O)[O-]
Isomeric SMILES C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-]
InChI InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H
InChI Key RJIWZDNTCBHXAL-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Nitroxoline is indicated for the treatment of acute and chronic infections of the lower urinary tract caused by susceptible bacteria. There is no information regarding current approval for clinical use of this drug on the US FDA or European Medicines Agency (EMA) websites, however individual European agencies do authorise its use. The US FDA and EMA have granted orphan drug designations for the use of nitroxoline for the treatment of neurofibromatosis type 1 (NF1).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06541847 A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 Phase 2 Interventional Healx Limited